Bernstein Sticks to Their Hold Rating for CVS Health (CVS)
Bernstein analyst Lance Wilkes maintained a Hold rating on CVS Health (CVS – Research Report) yesterday and set a price target of $52.00. The ...
Fox Business24d
Potential 'fungal contamination' leads to nationwide recall of popular brand of eye drops: FDA
The four impacted products, which are intended to be sterile, are sold under the brand names Equate, CVS Health and AACE Pharmaceuticals, and have expiration dates ranging from February 2024 to ...
2 Beaten-Down Dividend Stocks to Buy in 2025
Despite CVS Health's issues, its prospects and solid dividend program make it attractive for income seekers. Johnson & ...
Wells Fargo Reaffirms Their Buy Rating on CVS Health (CVS)
Wells Fargo analyst Stephen Baxter maintained a Buy rating on CVS Health (CVS – Research Report) on January 10 and set a price target of ...